Czech Republic: Plant Engineering Arxada to Invest 21 Million Dollars in its Industrial Biotechnology Facility

From Ahlam Rais

Arxada has plans to make the hefty investment in its Kouřim-based industrial biotechnological plant in Czech Republic. With this move, the company will be able to provide important infrastructure debottlenecking in line with expanded technological options as well as be able to increase its formulation capacity in order to cater to its growing customer base.

Related Companies

With this investment, Arxada is strengthening its capacity to support its expanding customer base with their highly interesting and often technologically challenging projects.
With this investment, Arxada is strengthening its capacity to support its expanding customer base with their highly interesting and often technologically challenging projects.
(Source: Deposit Photos)

Basel/Switzerland – Arxada, a global specialty chemicals business, has announced that it will invest 21 million dollars in its industrial biotechnological plant in Kouřim, Czech Republic, which serves the contract development and manufacturing organization (CDMO) part of its Specialty Products Solutions business. This investment provides important infrastructure debottlenecking in connection with expanded technological options and the addition of significant formulation capacity necessitated by Arxada’s growing customer base.

Antje Gerber, President, Specialty Products Solutions, Arxada, said: “With this investment, we are strengthening our capacity to support our expanding customer base with their highly interesting and often technologically challenging projects.”

Lukas von Hippel, VP, CDMO Business Line, Arxada, commented: “Our site in Kouřim is an integral part of our future strategy. Following the implementation of our new strategy in May 2020, we have seen more customers seeking our support in their new projects. Our business development team together with our process development team in Kouřim can speed up development and shorten time to market by over a year in some cases.”

Zdena Cermakova, Kouřim Site Head, Arxada, added: “We are seeing growing demand for CDMO projects in biotech.”

(ID:47830675)